{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T18:23:37Z","timestamp":1773339817101,"version":"3.50.1"},"reference-count":69,"publisher":"Frontiers Media SA","funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["102-2320-B-006-023-MY3"],"award-info":[{"award-number":["102-2320-B-006-023-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"DOI":"10.3389\/fmicb.2017.01411","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T08:54:43Z","timestamp":1500972883000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model"],"prefix":"10.3389","volume":"8","author":[{"given":"Yi-Wen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenn-Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Jane","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Hsiu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1128\/JCM.38.7.2706-2714.2000","article-title":"Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea.","volume":"38","author":"Alfa","year":"2000","journal-title":"J. Clin. Microbiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nrgastro.2010.190","article-title":"Clostridium difficile infection: epidemiology, risk factors and management.","volume":"8","author":"Ananthakrishnan","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.gtc.2006.03.009","article-title":"An update on diagnosis, treatment, and prevention of Clostridium difficile-associated disease.","volume":"35","author":"Aslam","year":"2006","journal-title":"Gastroenterol. Clin. North Am."},{"key":"B4","doi-asserted-by":"publisher","first-page":"579","DOI":"10.4161\/19490976.2014.969632","article-title":"Clostridium difficile virulence factors: insights into an anaerobic spore-forming pathogen.","volume":"5","author":"Awad","year":"2014","journal-title":"Gut Microbes"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1128\/IAI.01950-14","article-title":"An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo.","volume":"82","author":"Baliban","year":"2014","journal-title":"Infect. Immun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1146\/annurev.nu.15.070195.000343","article-title":"Regulation of tight-junction permeability during nutrient absorption across the intestinal epithelium.","volume":"15","author":"Ballard","year":"1995","journal-title":"Annu. Rev. Nutr."},{"key":"B7","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1086\/521865","article-title":"Historical perspectives on studies of Clostridium difficile and C. difficile infection.","author":"Bartlett","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.vaccine.2016.03.098","article-title":"Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.","volume":"34","author":"Bezay","year":"2016","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1517\/14712598.2015.1045872","article-title":"Fecal microbiota transplantation for Clostridium difficile infection: back to the future.","volume":"15","author":"Borgia","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"B10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0378-1119(96)00398-8","article-title":"Definition of the single integration site of the pathogenicity locus in Clostridium difficile.","volume":"181","author":"Braun","year":"1996","journal-title":"Gene"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00551-15","article-title":"Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections.","volume":"6","author":"Carter","year":"2015","journal-title":"mBio"},{"key":"B12","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.tim.2011.11.003","article-title":"The role of toxin A and toxin B in the virulence of Clostridium difficile.","volume":"20","author":"Carter","year":"2012","journal-title":"Trends Microbiol."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1088\/0957-4484\/22\/10\/105708","article-title":"The role of surface charge on the uptake and biocompatibility of hydroxyapatite nanoparticles with osteoblast cells.","volume":"22","author":"Chen","year":"2011","journal-title":"Nanotechnology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"9826","DOI":"10.1016\/j.biomaterials.2011.08.087","article-title":"A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery.","volume":"32","author":"Chen","year":"2011","journal-title":"Biomaterials"},{"key":"B15","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nature01451","article-title":"Regulated portals of entry into the cell.","volume":"422","author":"Conner","year":"2003","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/toxins8050134","article-title":"Clostridium difficile toxins A and B: insights into pathogenic properties and extraintestinal effects.","volume":"8","author":"Di Bella","year":"2016","journal-title":"Toxins"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-003-1754-7","article-title":"Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome.","volume":"29","author":"Dobson","year":"2003","journal-title":"Intensive Care Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijid.2006.04.003","article-title":"Toxin A-negative, toxin B-positive Clostridium difficile.","volume":"11","author":"Drudy","year":"2007","journal-title":"Int. J. Infect. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1056\/NEJMoa1216064","article-title":"Diverse sources of C. difficile infection identified on whole-genome sequencing.","volume":"369","author":"Eyre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.colsurfb.2015.02.042","article-title":"Surface charge effect on mucoadhesion of chitosan based nanogels for local anti-colorectal cancer drug delivery.","volume":"128","author":"Feng","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1016\/j.vaccine.2012.01.056","article-title":"Clostridium difficile: development of a novel candidate vaccine.","volume":"30","author":"Foglia","year":"2012","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.2147\/IJN.S36111","article-title":"The role of surface charge in cellular uptake and cytotoxicity of medical nanoparticles.","volume":"7","author":"Frohlich","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"B23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00417-002-0429-3","article-title":"Morphological evidence of M cells in healthy canine conjunctiva-associated lymphoid tissue.","volume":"240","author":"Giuliano","year":"2002","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"B24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/bmj.2.3632.244","article-title":"Insoluble precipitates in diphtheria and tetanus immunization.","volume":"2","author":"Glenny","year":"1930","journal-title":"Br. Med. J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.vaccine.2015.02.006","article-title":"The recombinant Lactococcus lactis oral vaccine induces protection against C. difficile spore challenge in a mouse model.","volume":"33","author":"Guo","year":"2015","journal-title":"Vaccine"},{"key":"B26","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0264-410X(02)00435-8","article-title":"Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres.","volume":"21","author":"Gutierro","year":"2002","journal-title":"Vaccine"},{"key":"B27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1111\/j.1469-0691.2012.03853.x","article-title":"Clostridium difficile infection in the community: a zoonotic disease?","volume":"18","author":"Hensgens","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-015-0171-x","article-title":"Recombinant lipoprotein-based vaccine candidates against C. difficile infections.","volume":"22","author":"Huang","year":"2015","journal-title":"J. Biomed. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1093\/infdis\/jiv184","article-title":"Proton-pump inhibitor exposure aggravates Clostridium difficile-associated colitis: evidence from a mouse model.","volume":"212","author":"Hung","year":"2015","journal-title":"J. Infect. Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1136\/jcp.2003.015875","article-title":"Colonic IgA producing cells and macrophages are reduced in recurrent and non-recurrent Clostridium difficile associated diarrhoea.","volume":"57","author":"Johal","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jinf.2009.03.010","article-title":"Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.","volume":"58","author":"Johnson","year":"2009","journal-title":"J. Infect."},{"key":"B32","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1128\/JCM.41.4.1543-1547.2003","article-title":"International typing study of toxin A-negative, toxin B-positive Clostridium difficile variants.","volume":"41","author":"Johnson","year":"2003","journal-title":"J. Clin. Microbiol."},{"key":"B33","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1128\/IAI.63.8.3166-3173.1995","article-title":"Selective neutralization of a bacterial enterotoxin by serum immunoglobulin A in response to mucosal disease.","volume":"63","author":"Johnson","year":"1995","journal-title":"Infect. Immun."},{"key":"B34","first-page":"15","article-title":"Non-invasive administration of biodegradable nano-carrier vaccines.","volume":"9","author":"Kalam","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"5344","DOI":"10.1016\/j.biomaterials.2007.08.015","article-title":"Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response.","volume":"28","author":"Kanchan","year":"2007","journal-title":"Biomaterials"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2016.05.001","article-title":"Vaccine technologies: from whole organisms to rationally designed protein assemblies.","volume":"120","author":"Karch","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ijpharm.2005.05.028","article-title":"Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticles.","volume":"301","author":"Katare","year":"2005","journal-title":"Int. J. Pharm."},{"key":"B38","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nrgastro.2015.220","article-title":"Breakthroughs in the treatment and prevention of Clostridium difficile infection.","volume":"13","author":"Kociolek","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0168-3659(97)00154-5","article-title":"Comparison of the effect of different chitosan salts and N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2).","volume":"51","author":"Kotze","year":"1998","journal-title":"J. Control. Release"},{"key":"B40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nature09397","article-title":"The role of toxin A and toxin B in Clostridium difficile infection.","volume":"467","author":"Kuehne","year":"2010","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s100960100550","article-title":"Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain.","volume":"20","author":"Kuijper","year":"2001","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1056\/NEJM200002103420604","article-title":"Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A.","volume":"342","author":"Kyne","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0140-6736(00)03592-3","article-title":"Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea.","volume":"357","author":"Kyne","year":"2001","journal-title":"Lancet"},{"key":"B44","doi-asserted-by":"publisher","first-page":"C25","DOI":"10.1016\/j.vaccine.2010.07.021","article-title":"Unmet needs in modern vaccinology: adjuvants to improve the immune response.","author":"Leroux-Roels","year":"2010","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1093\/cid\/ciu203","article-title":"Emergence of a ribotype 244 strain of Clostridium difficile associated with severe disease and related to the epidemic ribotype 027 strain.","volume":"58","author":"Lim","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1021\/bm0607776","article-title":"Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery.","volume":"8","author":"Lin","year":"2007","journal-title":"Biomacromolecules"},{"key":"B47","article-title":"Biodegradable nanocomplex. U.S. Patent No 20170043007","author":"Lin","year":"2017"},{"key":"B48","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/QCO.0000000000000320","article-title":"New and emerging therapies for Clostridium difficile infection.","volume":"29","author":"Martin","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.vaccine.2013.11.099","article-title":"Recombinant antigens based on toxins A and B of Clostridium difficile that evoke a potent toxin-neutralising immune response.","volume":"32","author":"Maynard-Smith","year":"2014","journal-title":"Vaccine"},{"key":"B50","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1517\/13543771003730425","article-title":"Recent advances in mucosal delivery of vaccines: role of mucoadhesive\/biodegradable polymeric carriers.","volume":"20","author":"Mishra","year":"2010","journal-title":"Expert Opin. Ther. Pat."},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/srep15023","article-title":"Clostridium difficile: new insights into the evolution of the pathogenicity locus","volume":"5","author":"Monot","year":"2015","journal-title":"Sci. Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.vetmic.2012.05.035","article-title":"Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate\/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.","volume":"160","author":"Moon","year":"2012","journal-title":"Vet. Microbiol."},{"key":"B53","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1093\/clinids\/16.Supplement_4.S239","article-title":"Elevated levels of serum immunoglobulins in asymptomatic carriers of Clostridium difficile.","author":"Mulligan","year":"1993","journal-title":"Clin. Infect. Dis."},{"key":"B54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.anaerobe.2016.04.014","article-title":"Immune responses induced by Clostridium difficile.","volume":"41","author":"Pechine","year":"2016","journal-title":"Anaerobe"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/nbt1332","article-title":"Exploiting lymphatic transport and complement activation in nanoparticle vaccines.","volume":"25","author":"Reddy","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002076","article-title":"A role for TLR4 in Clostridium difficile infection and the recognition of surface layer proteins.","volume":"7","author":"Ryan","year":"2011","journal-title":"PLoS Pathog."},{"key":"B57","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-3659(02)00127-X","article-title":"Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake.","volume":"82","author":"Sahoo","year":"2002","journal-title":"J. Control. Release"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1128\/JB.01765-07","article-title":"Bile salts and glycine as cogerminants for Clostridium difficile spores.","volume":"190","author":"Sorg","year":"2008","journal-title":"J. Bacteriol."},{"key":"B59","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2004.11.004","article-title":"Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea.","volume":"128","author":"Sougioultzis","year":"2005","journal-title":"Gastroenterology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.4161\/gmic.27712","article-title":"Vaccination against Clostridium difficile using toxin fragments: observations and analysis in animal models.","volume":"5","author":"Spencer","year":"2014","journal-title":"Gut Microbes"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1016\/j.vaccine.2012.04.045","article-title":"A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models.","volume":"30","author":"Tian","year":"2012","journal-title":"Vaccine"},{"key":"B62","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1146\/annurev.immunol.22.012703.104538","article-title":"Cell biology of antigen processing in vitro and in vivo.","volume":"23","author":"Trombetta","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1128\/IAI.00215-12","article-title":"A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection.","volume":"80","author":"Wang","year":"2012","journal-title":"Infect. Immun."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1080\/21645515.2015.1052352","article-title":"A chimeric protein comprising the glucosyltransferase and cysteine proteinase domains of toxin B and the receptor binding domain of toxin A induces protective immunity against Clostridium difficile infection in mice and hamsters.","volume":"11","author":"Wang","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"B65","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1128\/IAI.62.2.384-389.1994","article-title":"Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection.","volume":"62","author":"Warny","year":"1994","journal-title":"Infect. Immun."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymeth.2006.05.016","article-title":"Pathogen recognition and development of particulate vaccines: does size matter?","volume":"40","author":"Xiang","year":"2006","journal-title":"Methods"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1021\/bm101482r","article-title":"Surface charge affects cellular uptake and intracellular trafficking of chitosan-based nanoparticles.","volume":"12","author":"Yue","year":"2011","journal-title":"Biomacromolecules"},{"key":"B68","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.2147\/IJN.S70633","article-title":"Chitosan-coated poly(lactic-co-glycolic) acid nanoparticles as an efficient delivery system for Newcastle disease virus DNA vaccine.","volume":"9","author":"Zhao","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"B69","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.4161\/21645515.2014.980193","article-title":"Immune-based treatment and prevention of Clostridium difficile infection.","volume":"10","author":"Zhao","year":"2014","journal-title":"Hum. Vaccin. Immunother."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmicb.2017.01411\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T09:05:25Z","timestamp":1602579925000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmicb.2017.01411\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":69,"alternative-id":["10.3389\/fmicb.2017.01411"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2017.01411","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,25]]},"article-number":"1411"}}